Cargando…

Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis

BACKGROUND & AIMS: Prognostic tests are critical in the management of patients with cirrhosis and ascites. Biological tests or scores perform poorly in that situation. Mid-infrared fibre evanescent wave spectroscopy (MIR-FEWS) which allows for global serum metabolic profiling may provide more re...

Descripción completa

Detalles Bibliográficos
Autores principales: Le Corvec, Maëna, Jezequel, Caroline, Monbet, Valérie, Fatih, Nadia, Charpentier, Frédéric, Tariel, Hugues, Boussard-Plédel, Catherine, Bureau, Bruno, Loréal, Olivier, Sire, Olivier, Bardou-Jacquet, Edouard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5636102/
https://www.ncbi.nlm.nih.gov/pubmed/29020046
http://dx.doi.org/10.1371/journal.pone.0185997
_version_ 1783270384932487168
author Le Corvec, Maëna
Jezequel, Caroline
Monbet, Valérie
Fatih, Nadia
Charpentier, Frédéric
Tariel, Hugues
Boussard-Plédel, Catherine
Bureau, Bruno
Loréal, Olivier
Sire, Olivier
Bardou-Jacquet, Edouard
author_facet Le Corvec, Maëna
Jezequel, Caroline
Monbet, Valérie
Fatih, Nadia
Charpentier, Frédéric
Tariel, Hugues
Boussard-Plédel, Catherine
Bureau, Bruno
Loréal, Olivier
Sire, Olivier
Bardou-Jacquet, Edouard
author_sort Le Corvec, Maëna
collection PubMed
description BACKGROUND & AIMS: Prognostic tests are critical in the management of patients with cirrhosis and ascites. Biological tests or scores perform poorly in that situation. Mid-infrared fibre evanescent wave spectroscopy (MIR-FEWS) which allows for global serum metabolic profiling may provide more relevant information by measuring a wider range of metabolic parameters in serum. Here we present the accuracy of a MIR-FEWS based predictive model for the prognosis of 6 months survival in patients with ascites and cirrhosis. METHODS: Patients with ascites were prospectively included and followed up for 6 months. MIR-FEWS spectra were measured in serum samples. The most informative spectral variables obtained by MIR-FEWS were selected by FADA algorithm and then used to build the MIR model. Accuracy of this model was assessed by ROC curves and 90%/10% Monte Carlo cross-validation. MIR model accuracy for 6 months survival was compared to that of the Child-Pugh and MELD scores. RESULTS: 119 patients were included. The mean age was 57.36±13.70, the MELD score was 16.32±6.26, and the Child-Pugh score was 9.5±1.83. During follow-up, 23 patients died (20%). The MIR model had an AUROC for 6 months mortality of 0.90 (CI95: 0.88–0.91), the MELD 0.77 (CI95: 0.66–0.89) and Child-Pugh 0.76 (CI95: 0.66–0.88). MELD and Child-Pugh AUROCs were significantly lower than that of the MIR model (p = 0.02 and p = 0.02 respectively). Multivariate logistic regression analysis showed that MELD (p<0.05, OR:0.86;CI95:0.76–0.97), Beta blockers (p = 0.036;OR:0.20;CI95:0.04–0.90), and the MIR model (p<0.001; OR:0.50; CI95:0.37–0.66), were significantly associated with 6 months mortality. CONCLUSIONS: In this pilot study MIR-FEWS more accurately assess the 6-month prognosis of patients with ascites and cirrhosis than the MELD or Child-Pugh scores. These promising results, if confirmed by a larger study, suggest that mid infrared spectroscopy could be helpful in the management of these patients.
format Online
Article
Text
id pubmed-5636102
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-56361022017-10-30 Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis Le Corvec, Maëna Jezequel, Caroline Monbet, Valérie Fatih, Nadia Charpentier, Frédéric Tariel, Hugues Boussard-Plédel, Catherine Bureau, Bruno Loréal, Olivier Sire, Olivier Bardou-Jacquet, Edouard PLoS One Research Article BACKGROUND & AIMS: Prognostic tests are critical in the management of patients with cirrhosis and ascites. Biological tests or scores perform poorly in that situation. Mid-infrared fibre evanescent wave spectroscopy (MIR-FEWS) which allows for global serum metabolic profiling may provide more relevant information by measuring a wider range of metabolic parameters in serum. Here we present the accuracy of a MIR-FEWS based predictive model for the prognosis of 6 months survival in patients with ascites and cirrhosis. METHODS: Patients with ascites were prospectively included and followed up for 6 months. MIR-FEWS spectra were measured in serum samples. The most informative spectral variables obtained by MIR-FEWS were selected by FADA algorithm and then used to build the MIR model. Accuracy of this model was assessed by ROC curves and 90%/10% Monte Carlo cross-validation. MIR model accuracy for 6 months survival was compared to that of the Child-Pugh and MELD scores. RESULTS: 119 patients were included. The mean age was 57.36±13.70, the MELD score was 16.32±6.26, and the Child-Pugh score was 9.5±1.83. During follow-up, 23 patients died (20%). The MIR model had an AUROC for 6 months mortality of 0.90 (CI95: 0.88–0.91), the MELD 0.77 (CI95: 0.66–0.89) and Child-Pugh 0.76 (CI95: 0.66–0.88). MELD and Child-Pugh AUROCs were significantly lower than that of the MIR model (p = 0.02 and p = 0.02 respectively). Multivariate logistic regression analysis showed that MELD (p<0.05, OR:0.86;CI95:0.76–0.97), Beta blockers (p = 0.036;OR:0.20;CI95:0.04–0.90), and the MIR model (p<0.001; OR:0.50; CI95:0.37–0.66), were significantly associated with 6 months mortality. CONCLUSIONS: In this pilot study MIR-FEWS more accurately assess the 6-month prognosis of patients with ascites and cirrhosis than the MELD or Child-Pugh scores. These promising results, if confirmed by a larger study, suggest that mid infrared spectroscopy could be helpful in the management of these patients. Public Library of Science 2017-10-11 /pmc/articles/PMC5636102/ /pubmed/29020046 http://dx.doi.org/10.1371/journal.pone.0185997 Text en © 2017 Le Corvec et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Le Corvec, Maëna
Jezequel, Caroline
Monbet, Valérie
Fatih, Nadia
Charpentier, Frédéric
Tariel, Hugues
Boussard-Plédel, Catherine
Bureau, Bruno
Loréal, Olivier
Sire, Olivier
Bardou-Jacquet, Edouard
Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis
title Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis
title_full Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis
title_fullStr Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis
title_full_unstemmed Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis
title_short Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis
title_sort mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5636102/
https://www.ncbi.nlm.nih.gov/pubmed/29020046
http://dx.doi.org/10.1371/journal.pone.0185997
work_keys_str_mv AT lecorvecmaena midinfraredspectroscopyofserumapromisingnoninvasivemethodtoassessprognosisinpatientswithascitesandcirrhosis
AT jezequelcaroline midinfraredspectroscopyofserumapromisingnoninvasivemethodtoassessprognosisinpatientswithascitesandcirrhosis
AT monbetvalerie midinfraredspectroscopyofserumapromisingnoninvasivemethodtoassessprognosisinpatientswithascitesandcirrhosis
AT fatihnadia midinfraredspectroscopyofserumapromisingnoninvasivemethodtoassessprognosisinpatientswithascitesandcirrhosis
AT charpentierfrederic midinfraredspectroscopyofserumapromisingnoninvasivemethodtoassessprognosisinpatientswithascitesandcirrhosis
AT tarielhugues midinfraredspectroscopyofserumapromisingnoninvasivemethodtoassessprognosisinpatientswithascitesandcirrhosis
AT boussardpledelcatherine midinfraredspectroscopyofserumapromisingnoninvasivemethodtoassessprognosisinpatientswithascitesandcirrhosis
AT bureaubruno midinfraredspectroscopyofserumapromisingnoninvasivemethodtoassessprognosisinpatientswithascitesandcirrhosis
AT lorealolivier midinfraredspectroscopyofserumapromisingnoninvasivemethodtoassessprognosisinpatientswithascitesandcirrhosis
AT sireolivier midinfraredspectroscopyofserumapromisingnoninvasivemethodtoassessprognosisinpatientswithascitesandcirrhosis
AT bardoujacquetedouard midinfraredspectroscopyofserumapromisingnoninvasivemethodtoassessprognosisinpatientswithascitesandcirrhosis